138 related articles for article (PubMed ID: 36001637)
1. Editorial Comments to Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
Kato M
Int J Urol; 2022 Nov; 29(11):1330. PubMed ID: 36001637
[No Abstract] [Full Text] [Related]
2. Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
Yang X; Allen JC; Aslim EJ; Tay KJ; Yuen SPJ; Kanesvaran R; Chua MLK; Chong TW; Ho SSH; Lee LS
Int J Urol; 2022 Nov; 29(11):1322-1330. PubMed ID: 36000794
[TBL] [Abstract][Full Text] [Related]
3. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG
BMJ Open; 2020 Jan; 10(1):e033667. PubMed ID: 31988233
[TBL] [Abstract][Full Text] [Related]
5. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
[TBL] [Abstract][Full Text] [Related]
8. Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.
Ilario EN; Bastos DA; Guglielmetti GB; Murta CB; Cardili L; Cordeiro MD; Junior JP; Coelho RF; Nahas WC
Clin Genitourin Cancer; 2023 Feb; 21(1):43-54. PubMed ID: 36428171
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
Galsky MD; Xie W; Nakabayashi M; Ross RW; Fennessy FM; Tempany CM; Choueiri TK; Khine K; Kantoff PW; Taplin ME; Oh WK
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):266-70. PubMed ID: 23712318
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
Ravi P; Kwak L; Xie W; Kelleher K; Acosta AM; McKay RR; Kibel AS; Taplin ME
J Urol; 2022 Oct; 208(4):838-845. PubMed ID: 36082554
[TBL] [Abstract][Full Text] [Related]
13. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
Pietzak EJ; Eastham JA
Curr Urol Rep; 2016 May; 17(5):37. PubMed ID: 26968417
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents.
Tafuri A; Cerruto MA; Antonelli A
Curr Drug Targets; 2021; 22(1):68-76. PubMed ID: 32564752
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.
Powell IJ; Tangen CM; Miller GJ; Lowe BA; Haas G; Carroll PR; Osswald MB; DeVERE WHITE R; Thompson IM; Crawford ED
J Urol; 2002 Nov; 168(5):2016-9. PubMed ID: 12394698
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.
Devos G; Vansevenant B; De Meerleer G; Clinckaert A; Devlies W; Claessens F; Graefen M; Steuber T; Briganti A; de la Taille A; Van Poppel H; Joniau S
World J Urol; 2021 Sep; 39(9):3177-3185. PubMed ID: 33580296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
